Segment and Geographic Information (Details) - USD ($) $ in Millions		3 Months Ended															12 Months Ended
		Dec. 31, 2020		Sep. 30, 2020	[2]	Jun. 30, 2020	[3]	Mar. 31, 2020	Dec. 31, 2019		Sep. 28, 2019	[5]	Jun. 29, 2019	[6]	Mar. 30, 2019	[7]	Dec. 31, 2020		Dec. 31, 2019		Dec. 31, 2018
Segment Reporting Information [Line Items]
Net sales		$ 1,289.5	[1]	$ 1,213.7		$ 1,219.1		$ 1,341.0	$ 1,322.8	[4]	$ 1,191.1		$ 1,149.0		$ 1,174.5		$ 5,063.3	[8]	$ 4,837.4	[8]	$ 4,731.7	[8]
Operating income (loss)																	$ 115.4		$ 204.8		$ 236.5
Operating income %																	2.30%		4.20%		5.00%
Total assets		11,488.4							11,301.4								$ 11,488.4		$ 11,301.4		$ 10,983.4
Capital expenditures																	170.4		137.7		102.7
Property, plant and equipment, net		996.0							902.8								996.0		902.8		829.1
Depreciation/amortization																	384.8		396.5		423.6
Change in financial assets		122.3	[1]	$ (22.2)		$ (2.1)		$ (1.6)	(3.6)	[4]	$ (2.6)		$ (5.5)		$ (10.4)		96.4		(22.1)		(188.7)
CSCA
Segment Reporting Information [Line Items]
Net sales	[9]																2,693.0		2,487.7		2,411.6
CSCI
Segment Reporting Information [Line Items]
Net sales																	1,395.2		1,382.2		1,399.3
RX
Segment Reporting Information [Line Items]
Net sales																	975.1		967.5		920.8
Ireland
Segment Reporting Information [Line Items]
Net sales																	29.8		23.4		25.7
Property, plant and equipment, net		20.3							9.3								20.3		9.3
United States
Segment Reporting Information [Line Items]
Net sales	[8]																3,441.1		3,225.6		3,098.3
Property, plant and equipment, net		678.2							614.5								678.2		614.5
Europe
Segment Reporting Information [Line Items]
Net sales	[8],[10]																1,350.6		1,335.8		$ 1,347.6
Property, plant and equipment, net	[11]	169.7							146.8								169.7		146.8
Israel
Segment Reporting Information [Line Items]
Property, plant and equipment, net		90.7							86.1								90.7		86.1
All other countries
Segment Reporting Information [Line Items]
Property, plant and equipment, net		57.4							55.4								$ 57.4		$ 55.4
Walmart | Net sales | Customer Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk percentage																	13.30%		13.00%		12.80%
Operating Segments | CSCA
Segment Reporting Information [Line Items]
Net sales																	$ 2,693.0		$ 2,487.7		$ 2,411.6
Operating income (loss)																	$ 472.0		$ 414.0		$ 174.4
Operating income %																	17.50%		16.60%		7.20%
Total assets		4,443.0							3,990.2								$ 4,443.0		$ 3,990.2		$ 3,571.7
Capital expenditures																	126.0		98.4		65.0
Property, plant and equipment, net		675.7							599.8								675.7		599.8		530.3
Depreciation/amortization																	103.6		97.4		104.8
Change in financial assets																	0.0		0.0		0.0
Operating Segments | CSCI
Segment Reporting Information [Line Items]
Net sales																	1,395.2		1,382.2		1,399.3
Operating income (loss)																	$ 32.3		$ 19.6		$ 6.8
Operating income %																	2.30%		1.40%		0.50%
Total assets		4,872.4							4,682.7								$ 4,872.4		$ 4,682.7		$ 4,613.0
Capital expenditures																	28.8		18.8		19.1
Property, plant and equipment, net		163.5							149.9								163.5		149.9		154.8
Depreciation/amortization																	177.8		194.3		219.2
Change in financial assets																	0.0		0.0		0.0
Operating Segments | RX
Segment Reporting Information [Line Items]
Net sales																	975.1		967.5		920.8
Operating income (loss)																	$ (177.7)		$ 2.6		$ 214.6
Operating income %																	(18.20%)		0.30%		23.30%
Total assets		2,173.0							2,628.5								$ 2,173.0		$ 2,628.5		$ 2,798.7
Capital expenditures																	15.6		20.5		18.6
Property, plant and equipment, net		156.8							153.1								156.8		153.1		144.0
Depreciation/amortization																	103.4		104.8		99.6
Change in financial assets																	0.0		0.0		0.0
Unallocated
Segment Reporting Information [Line Items]
Net sales																	0.0		0.0		0.0
Operating income (loss)																	$ (211.2)		$ (231.4)		$ (159.3)
Operating income %																	0.00%		0.00%		0.00%
Total assets		0.0							0.0								$ 0.0		$ 0.0		$ 0.0
Capital expenditures																	0.0		0.0		0.0
Property, plant and equipment, net		$ 0.0							$ 0.0								0.0		0.0		0.0
Depreciation/amortization																	0.0		0.0		0.0
Change in financial assets																	$ 96.4		$ (22.1)		$ (188.7)

[1] Includes change in financial assets of $122.3 million and impairment charges of $144.4 million.

[2] Includes impairment charges of $202.4 million, change in financial assets of $22.2 million and loss on early debt extinguishment of $20.0 million.

[3] Includes Rosemont Pharmaceuticals business pre-tax loss of $21.1 million.

[4] Includes impairment charges of $141.6 million.

[5] Includes animal health divestiture pre-tax gain of $71.7 million, Ranitidine market withdrawal charges of $18.4 million, acquisition-related charges and contingent consideration adjustments of $18.1 million, and impairment charges of $10.9 million.

[6] Includes impairment charges of $27.8 million and restructuring charges and other termination benefits of $12.2 million.

[7] Includes change in financial assets of $10.4 million.

[8] The net sales by geography is derived from the location of the entity that sells to a third party.

[9] Includes net sales from our OTC contract manufacturing business.

[10] Includes Ireland net sales of $29.8 million, $23.4 million, and $25.7 million for the years ended December 31, 2020, December 31, 2019, and December 31, 2018, respectively.

[11] Includes Ireland Property, plant and equipment, net of $20.3 million and $9.3 million, for the years ended December 31, 2020 and December 31, 2019, respectively.